DCH Auriga - Healthcare
Concise Prescribing Info
Pulmonary arterial HTN (PAH) (idiopathic or heritable PAH & PAH associated w/ connective tissue diseases) in patients w/ WHO Functional Class III-IV symptoms to improve exercise capacity.
Dosage/Direction for Use
IV Short-term (acute) dose ranging: Initiate at 2 ng/kg/min, increased by increments of 2 ng/kg/min every ≥15 min until max haemodynamic benefit or dose‑limiting pharmacological effects are elicited. Identify lower dose if initial infusion rate is not tolerated. Long-term continuous infusion: Initiate at 4 ng/kg/min less than the max tolerated infusion rate determined during short-term dose-ranging.
Hypersensitivity. CHF arising from severe left ventricular dysfunction. Do not use chronically in patients who develop pulmonary oedema during dose‑ranging.
Special Precautions
Decreasing pH of diluted soln w/ further dilution; restrict peripheral IV use to short duration only, using low conc. Avoid extravasation during administration; consequent risk of tissue damage due to high pH of final infusion soln. Potent pulmonary & systemic vasodilator. Potent inhibitor of platelet aggregation. Reduce dose or discontinue infusion if excessive hypotension occurs. Monitor BP & heart rate during administration. Effects on heart rate may be masked w/ concomitant drugs which affect CV reflexes. Patients w/ CAD. Elevated serum glucose levels. Pulmonary oedema during dose-ranging. Avoid abrupt w/drawal or interruption of infusion (except in life-threatening situations). May affect ability to drive & operate machinery. Discontinue breastfeeding during treatment. Elderly >65 yr. Childn.
Adverse Reactions
Headache; facial flushing; nausea, vomiting, diarrhoea; jaw pain; pain. Sepsis, septicaemia (mostly related to delivery system for Veletri); decreased platelet count, bleeding at various sites (eg, pulmonary, GI, epistaxis, intracranial, post-procedural, retroperitoneal); anxiety, nervousness; tachycardia, bradycardia; hypotension; abdominal colic, sometimes reported as abdominal discomfort; rash; arthralgia; pain at inj site, chest pain.
Drug Interactions
Vasodilator effects may augment or be augmented w/ other vasodilators. Reduced thrombolytic efficacy of tissue plasminogen activator (t-PA). Increased bleeding risk w/ NSAIDs or other drugs affecting platelet aggregation. Elevated conc of digoxin.
ATC Classification
B01AC09 - epoprostenol ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Veletri powd for soln for infusion 0.5 mg
Veletri powd for soln for infusion 1.5 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in